Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation

Journal of the American College of Cardiology

Volumn 68, Issue 13, 2016, Pages 1389-1401

  Chan, Yi Hsin ^a,b   Kuo, Chi Tai ^a,b   Yeh, Yung Hsin ^a,b   Chang, Shang Hung ^a,b   Wu, Lung Sheng ^a,b   Lee, Hsin Fu ^a,b   Tu, Hui Tzu ^b   See, Lai Chu ^a,b,c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

direct thrombin inhibitor; factor Xa inhibitor; hemorrhage; mortality; warfarin

Indexed keywords

DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR;

AGED; ARTICLE; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONVALVULAR ATRIAL FIBRILLATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; RISK REDUCTION; SYSTEMIC EMBOLISM; TAIWAN; TREATMENT OUTCOME; VERY ELDERLY; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMICALLY INDUCED; COMPARATIVE STUDY; COMPLICATION; MIDDLE AGED; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTITHROMBINS; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; COHORT STUDIES; DABIGATRAN; FACTOR XA INHIBITORS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RIVAROXABAN; STROKE; THROMBOEMBOLISM; WARFARIN;

EID: 84990913267     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.06.062     Document Type: Article

References (31)

1. 1 Zoni-Berisso, M., Lercari, F., Carazza, T., Domenicucci, S., Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 6 (2014), 213–220.
2. 2 Lin, H.J., Wolf, P.A., Kelly-Hayes, M., et al. Stroke severity in atrial fibrillation. The Framingham study. Stroke 27 (1996), 1760–1764.
3. 3 Hart, R.G., Pearce, L.A., Aguilar, M.I., Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146 (2007), 857–867.
4. 4 Lip, G.Y., Edwards, S.J., Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res 118 (2006), 321–333.
5. 5 Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
6. 6 Patel, M.R., Mahaffey, K.W., Garg, J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.
7. 7 Graham, D.J., Reichman, M.E., Wernecke, M., et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 131 (2015), 157–164.
8. 8 Sherwood, M.W., Nessel, C.C., Hellkamp, A.S., et al. Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF trial. J Am Coll Cardiol 66 (2015), 2271–2281.
9. 9 Shen, A.Y., Yao, J.F., Brar, S.S., Jorgensen, M.B., Chen, W., Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 50 (2007), 309–315.
10. 10 Lip, G.Y., Wang, K.L., Chiang, C.E., Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal. Int J Cardiol 180 (2015), 246–254.
11. 11 Wang, K.L., Lip, G.Y., Lin, S.J., Chiang, C.E., Non-vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation: meta-analysis. Stroke 46 (2015), 2555–2561.
12. 12 Chan, Y.H., Yen, K.C., See, L.C., et al. Cardiovascular, bleeding, and mortality risks of dabigatran in Asians with nonvalvular atrial fibrillation. Stroke 47 (2016), 441–449.
13. 13 National Health Insurance Administration, Ministry of Health and Welfare, Taiwan. The national health insurance statistics 2014. Available at: http://www.nhi.gov.tw/English/webdata/webdata.aspx?menu=11&menu_id=296&WD_ID=296&webdata_id=4835. Accessed January 14, 2016.
14. 14 Austin, P.C., The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med 33 (2014), 1242–1258.
15. 15 Wong, K.S., Hu, D.Y., Oomman, A., et al. Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial. Stroke 45 (2014), 1739–1747.
16. 16 Giugliano, R.P., Ruff, C.T., Braunwald, E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369 (2013), 2093–2104.
17. 17 Hori, M., Matsumoto, M., Tanahashi, N., et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation—the J-ROCKET AF study. Circ J 76 (2012), 2104–2111.
18. 18 Singer, D.E., Hellkamp, A.S., Piccini, J.P., et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc, 2, 2013, e000067.
19. 19 Hori, M., Connolly, S.J., Zhu, J., et al. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 44 (2013), 1891–1896.
20. 20 Heck, A.M., DeWitt, B.A., Lukes, A.L., Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm 57 (2000), 1221–1227.
21. 21 Chan, P.H., Huang, D., Hai, J.J., et al. Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation. Heart Rhythm 13 (2015), 366–373.
22. 22 Wen, C.P., Cheng, T.Y., Tsai, M.K., et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462,293 adults in Taiwan. Lancet 371 (2008), 2173–2182.
23. 23 Hylek, E.M., Evans-Molina, C., Shea, C., Henault, L.E., Regan, S., Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115 (2007), 2689–2696.
24. 24 Maura, G., Blotiere, P.O., Bouillon, K., et al. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Circulation 132 (2015), 1252–1260.
25. 25 Tepper, P., Mardekian, J., Masseria, C., et al. Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients on apixaban, dabigatran, rivaroxaban: cohorts comprising new initiators and/or switchers from warfarin (abstr). Eur Heart J, 36, 2015, 339.
26. 26 Mahaffey, K.W., Wojdyla, D., Hankey, G.J., et al. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. Ann Intern Med 158 (2013), 861–868.
27. 27 Ezekowitz, M.D., Wallentin, L., Connolly, S.J., et al. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation 122 (2010), 2246–2253.
28. 28 Chao, T.F., Liu, C.J., Tuan, T.C., et al. Rate-control treatment and mortality in atrial fibrillation. Circulation 132 (2015), 1604–1612.
29. 29 Chao, T.F., Wang, K.L., Liu, C.J., et al. Age threshold for increased stroke risk among patients with atrial fibrillation: a nationwide cohort study from Taiwan. J Am Coll Cardiol 66 (2015), 1339–1347.
30. 2-VASc score (beyond sex) receive oral anticoagulation?. J Am Coll Cardiol 65 (2015), 635–642.
31. 2-VASc score for refining stroke risk stratification in “low-risk” Asian patients with atrial fibrillation. J Am Coll Cardiol 64 (2014), 1658–1665.